Drug intelligence / Profile preview

cannabidiol + vigabatrin

Development stage
Unknown
Lead developer
Jazz Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Cannabidiol + vigabatrin is a **combination therapy** comprising cannabidiol (CBD), a non-psychoactive cannabinoid derived from cannabis, and vigabatrin, a small-molecule antiepileptic agent. This combination is studied as an adjunctive regimen for **infantile spasms**, in which CBD is given alongside vigabatrin as first-line therapy. CBD acts via multiple mechanisms, including modulation of endocannabinoid and non-endocannabinoid receptors, exerting anti-seizure, neuroprotective, and anti-inflammatory effects. Vigabatrin irreversibly inhibits GABA transaminase (GABA-T), increasing GABA levels in the brain and reducing neuronal excitability. The combination is being investigated primarily for more effective initial control of infantile spasms, a severe pediatric epilepsy.[1][5][9]

02

Targets

ABAT (4-aminobutyrate aminotransferase)GABRR (GABA-A receptor subunit rho)CNR1 (Cannabinoid receptor 1)HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)

Beyond the preview

Go deeper on cannabidiol + vigabatrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + vigabatrin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call